23 May 2013
Keywords: Astellas, Mirabegron, Overactive bladder, OAB, USA, FDA, Advisory panel
Article | 10 April 2012
The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) said last week that the Reproductive Health Drugs Advisory Committee ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 April 2012
22 May 2013
© 2013 thepharmaletter.com